Tackling Antimicrobial Resistance Through Swift & Seamless Antibiotic Development

Innoviva Specialty Therapeutics, Recipharm, and ACS Dobfar have joined forces to tackle the challenge of antimicrobial resistance (AMR) by developing a new antibiotic. The collaboration addresses the lack of expertise in antibiotic development and the need for advanced filling capabilities and scalability. By partnering with Recipharm, ACS Dobfar and Innoviva Specialty Therapeutics were able to overcome these obstacles and accelerate the timeline from clinical to process validation through the FDA. The collaboration also emphasized delivering quality within tight project deadlines.

Recipharm played a crucial role in supporting the project from the clinical phase to commercialization at its specialized Brescia site in Italy. The partnership focused on strategic batch management to streamline the regulatory process, resulting in the successful FDA approval of the antibiotic. This achievement highlights the power of collaboration and expertise in advancing healthcare.

Moving forward, Innoviva Specialty Therapeutics plans to expand the antibiotic's presence in new markets, with ongoing support from Recipharm. This partnership demonstrates the importance of collaboration in combating AMR and developing much-needed antibiotics. Read the case study to review how by pooling resources and expertise, the pharmaceutical industry can make significant strides in addressing this global health challenge.